Since the recognition of EGFR as a therapeutic target, EGFR tyrosine kinase inhibitors (TKIs) have been widely used in treating NSCLC patients, which has been a major breakthrough for lung cancer treatment. This evidence concerns the gene EGFR and lung carcinoma.